Eli Lilly and Company $LLY Stock Position Raised by JT Stratford LLC

JT Stratford LLC raised its holdings in Eli Lilly and Company (NYSE:LLY) by 27.1% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 4,212 shares of the company’s stock after acquiring an additional 898 shares during the quarter. JT Stratford LLC’s holdings in Eli Lilly and Company were worth $3,214,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Sumitomo Mitsui Financial Group Inc. bought a new stake in Eli Lilly and Company during the second quarter worth approximately $27,000. Evolution Wealth Management Inc. bought a new position in shares of Eli Lilly and Company in the second quarter valued at approximately $29,000. Steph & Co. raised its position in shares of Eli Lilly and Company by 290.0% in the third quarter. Steph & Co. now owns 39 shares of the company’s stock valued at $30,000 after purchasing an additional 29 shares during the period. Financial Gravity Companies Inc. acquired a new stake in shares of Eli Lilly and Company in the second quarter worth $31,000. Finally, Bare Financial Services Inc boosted its holdings in shares of Eli Lilly and Company by 263.6% during the 2nd quarter. Bare Financial Services Inc now owns 40 shares of the company’s stock worth $31,000 after buying an additional 29 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Trading Down 0.4%

Shares of LLY stock opened at $1,004.12 on Thursday. The company has a market capitalization of $947.25 billion, a P/E ratio of 43.75, a P/E/G ratio of 1.17 and a beta of 0.40. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,133.95. The company has a quick ratio of 1.19, a current ratio of 1.58 and a debt-to-equity ratio of 1.54. The firm has a 50-day moving average price of $1,049.25 and a 200 day moving average price of $936.91.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $7.54 EPS for the quarter, topping analysts’ consensus estimates of $7.48 by $0.06. The company had revenue of $19.29 billion for the quarter, compared to analyst estimates of $17.85 billion. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The business’s revenue was up 42.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $5.32 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be paid a $1.73 dividend. The ex-dividend date of this dividend is Friday, February 13th. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 dividend on an annualized basis and a yield of 0.7%. Eli Lilly and Company’s payout ratio is 30.15%.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on LLY shares. Berenberg Bank upped their price target on shares of Eli Lilly and Company from $950.00 to $1,050.00 and gave the company a “hold” rating in a report on Thursday, February 19th. Wall Street Zen downgraded Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 31st. Wells Fargo & Company raised their target price on Eli Lilly and Company from $1,200.00 to $1,280.00 and gave the company an “overweight” rating in a report on Thursday, February 5th. Argus lifted their price target on Eli Lilly and Company from $930.00 to $1,200.00 and gave the stock a “buy” rating in a research report on Monday, February 9th. Finally, Rothschild & Co Redburn increased their price objective on Eli Lilly and Company from $775.00 to $830.00 and gave the company a “neutral” rating in a research report on Monday, January 26th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and five have given a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $1,229.59.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Shareholders approved Eli Lilly’s acquisition of Ventyx Biosciences, clearing a regulatory/transactional hurdle that extends Lilly’s pipeline and inorganic growth options. Ventyx Merger Approved
• Positive Sentiment: Lilly advanced remternetug (an Alzheimer’s asset) testing in China, broadening its geographic trial footprint and potentially improving future market access in a key region for neurodegenerative therapies. Remternetug China Trial Update
• Positive Sentiment: Lilly progressed a new oral diabetes candidate in China (Phase 1 update), supporting continued expansion of its diabetes/GLP-1 franchise beyond injectable offerings. Pipeline diversification can support longer-term revenue growth. Oral Diabetes Drug in China
• Positive Sentiment: Analyst/market commentary (Zacks) flags Lilly as a strong momentum name and notes elevated investor attention—coverage that can support continued flows and multiple expansion if momentum resumes. Zacks Momentum Coverage
• Neutral Sentiment: The DIA 2026 Global Annual Meeting will bring cross-sector life-sciences attention to product development themes; this is industry-positive but not a direct LLY catalyst. DIA 2026 Meeting
• Neutral Sentiment: Broader market rotation stories (e.g., articles arguing biotech is outperforming AI) could redirect funds into pharma/biotech, a potential tailwind but uncertain for any single name. Biotech vs AI Rotation
• Neutral Sentiment: Competitor/sector updates (e.g., J&J immunology & neuroscience growth) highlight competitive dynamics in immunology/neuroscience but are not an immediate direct hit to Lilly’s headline momentum. JNJ Sector Update
• Negative Sentiment: Valuation and momentum checks note cooling short-term performance after years of strong gains; concerns about stretched multiples are pressuring sentiment and limiting upside near term. Valuation Check
• Negative Sentiment: Some retail/investing commentary recommends reallocating from Lilly into other “unstoppable” stocks, creating narrative-driven outflows and headline risk for momentum investors. Fool: Alternatives to Lilly

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.